AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.
Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...
Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...
Shares of Axsome Therapeutics ( AXSM -0.40%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...